This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA

David Tabatadze, PhD
President and CEO at ZATA Pharmaceuticals
Speaker

Profile

Dr. David R. Tabatadze is President and CEO of ZATA Pharmaceuticals, specializing in oligonucleotide (ON) chemistry and backbone modification technologies. Trained under Dr. Paul Zamecnik, the father of antisense oligonucleotides, he has contributed to the development of novel ON modifications and phosphoramidite-based chemistries. His work includes early advances in synthetic oligonucleotides for gene correction and the design of phosphotriester-based platforms enabling backbone engineering, improved stability, and enhanced cellular uptake. Dr. Tabatadze has led the development of scalable ON chemistries compatible with ASO, siRNA, and CRISPR modalities, supported by multiple patents and decades of experience in nucleic acid science.

Agenda Sessions

  • Rethinking the Oligonucleotide Backbone: A New Approach to RNA Therapeutic Design

    9:30am